In this paper we report our experience with the double route of administration of 5-FU (i.v. bolus and continues infusion) and the triple modulation of 5-FU with methotrexate, folinic acid and cisplatin in the treatment of advanced gastric cancer. Our results show 21.4% of response rate and 6 months of median overall survival. The toxicity was severe and mainly gastrointestinal. This schedule has a low efficacy in the treatment of advanced gastric cancer, and its activity is the same of that obtained FAM regimen, but lower when compared to FAMTX and EAP. The low dose intensity of 5-FU due to gastrointestinal toxicity and the lack of anthraciclin in this regimen are probably responsible of the low antibastic effect.
Triple modulation of 5-flourouracil with methotrexate, folinic acid and cisplain in the treatment of advanced gastric cancer: A phase II study
Landriscina M.;
1997-01-01
Abstract
In this paper we report our experience with the double route of administration of 5-FU (i.v. bolus and continues infusion) and the triple modulation of 5-FU with methotrexate, folinic acid and cisplatin in the treatment of advanced gastric cancer. Our results show 21.4% of response rate and 6 months of median overall survival. The toxicity was severe and mainly gastrointestinal. This schedule has a low efficacy in the treatment of advanced gastric cancer, and its activity is the same of that obtained FAM regimen, but lower when compared to FAMTX and EAP. The low dose intensity of 5-FU due to gastrointestinal toxicity and the lack of anthraciclin in this regimen are probably responsible of the low antibastic effect.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
